Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis
Kim A. Staats1,2,3,4† 
Susann Schönefeldt3,4† 
Marike Van Rillaer3,4 Annelies Van Hoecke1,2 
Philip Van Damme1,2,5 Wim Robberecht1,2,5 
Adrian Liston3,4*† 
Ludo Van Den Bosch1,2*†- 1KU Leuven Laboratory of Neurobiology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium
- 2VIB Vesalius Research Center, KU Leuven, Leuven, Belgium
- 3VIB Autoimmune Genetics Laboratory, KU Leuven, Leuven, Belgium
- 4Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
- 5Neurology, University Hospitals Leuven, Leuven, Belgium
Beta-2 microglobulin (β2m) is an essential component of the major histocompatibility complex (MHC) class I proteins and in the nervous system β2m is predominantly expressed in motor neurons. As β2m can promote nerve regeneration, we investigated its potential role in amyotrophic lateral sclerosis (ALS) by investigating its expression level as well as the effect of genetically removing β2m on the disease process in mutant superoxide dismutase 1 (SOD1G93A) mice, a model of ALS. We observed a strong upregulation of β2m in motor neurons during the disease process and ubiquitous removal of β2m dramatically shortens the disease duration indicating that β2m plays an essential and positive role during the disease process. We hypothesize that β2m contributes to plasticity that is essential for muscle reinnervation. Absence of this plasticity will lead to faster muscle denervation and counteracting this process could be a relevant therapeutic target.
Introduction
Major histocompatibility complex (MHC) class I proteins were originally discovered based on their critical role in the immune system, however immune-independent functions in the nervous system have recently been identified (Huh et al., 2000; Elmer and Mcallister, 2012). Beta-2 microglobulin (β2m) is an essential component of MHC class I molecules, being required for expression of all MHC class I on the cell surface. Within the central nervous system β2m has a predominantly motor neuronal expression pattern (Linda et al., 1998, 1999; Thams et al., 2009). This protein is therefore a candidate to contribute to the selective vulnerability of such motor neurons during amyotrophic lateral sclerosis (ALS).
ALS is a progressive neurodegenerative disease, characterized by the selective loss of motor neurons and the denervation of muscle fibers, resulting in muscle weakness and paralysis. In Europe, the disease has an annual incidence of 2.7 cases per 100,000 people (Logroscino et al., 2010) and the disease duration post-diagnosis is 3–5 years. In 10% of patients, ALS is a familial disease and 20% of these familial ALS patients contain mutations in the gene encoding superoxide dismutase 1 (SOD1). Based on these mutations, ALS rodent models have been generated that predictably mimic the patient disease process (Julien and Kriz, 2006). As the disease progression is indistinguishable between familial and sporadic ALS, common disease mechanisms are predicted. One of these mechanisms is decreased (peripheral) neuronal plasticity that can influence the ability of neuronal networks to compensate for a loss of (motor) neurons in the network. β2m is expressed in motor neurons in the lumbar spinal cord (Linda et al., 1999) as well as in motor axons (Thams et al., 2009). Additionally, β2m promotes recovery after axotomy (Linda et al., 1998; Oliveira et al., 2004) and sciatic nerve crush (Oliveira et al., 2004), which implies that it may be of importance in ALS too.
In this study, we investigated the role of β2m in ALS mice. To this end, we assessed the gene expression of β2m and interbred mice genetically lacking β2m with SOD1G93A mice and assessed survival and disease pathology.
Materials and Methods
Animal Experiments
Mice overexpressing human wild-type SOD1 (SOD1WT) or human SOD1G93A and β2m knockout mice were purchased from The Jackson Laboratories (Bar Harbor, USA) and maintained on a C57BL/6 background. The SOD1G93A and β2m knockout were interbred allowing for approx. 50% of the mice to be littermate controlled in this study. Chow and water were provided ad libitum and mice were housed in the specific pathogen free animal facility of the KU Leuven under standard conditions according to the guidelines of the KU Leuven. End stage was defined as the age at which mice could no longer right themselves within 30 s when placed on their back. End stage is used as a measurement of survival and is the condition at which mice are euthanized to prevent further suffering. Disease onset was defined as the age at which mouse weight dropped below 90% of the average day 90–105 weight. The animal caretakers and scientists were blinded to the genotypes of the mice when assessing “end stage”. All animal experiments were performed with the approval of the Animal Ethical Committee of KU Leuven (020/2010).
Laser Dissection Microscopy
Murine spinal cords were snap-frozen in Tissue-Tec (Sakura Finetek Europe, Alphen aan de Rijn, The Netherlands) to make cryostat sections of 20-μm thickness. Then, cresyl violet–stained motor neurons, located in the ventral horn of the lumbar spinal cord, were collected on membrane slides 1.0 PEN (Carl Zeiss AG, Oberkochen, Germany), using dissection by a laser-dissection microscope (Carl Zeiss AG) and capturing in Adhesive Cap 500 opaque (Carl Zeiss AG). Only motor neurons in which the nucleus was visible and with soma area > 250 μm2, were collected. At least 1,500 motor neurons were dissected for each animal.
Quantitative PCR
Isolation of mRNA was performed using the TriPure (Roche, Basel, Switzerland) method and the RNeasy kit (Qiagen, Venlo, The Netherlands). Reverse transcriptase polymerase chain reaction (PCR) used random hexamers (Life Technologies, Carlsbad, USA) and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV RT; Invitrogen, Carlsbad, USA). Quantitative PCR (qPCR) was performed with the StepOnePlus (Life Technologies) and TaqMan Universal PCR Master Mix (Life Technologies). Gene expression assays were purchased from Life Technologies and IDT DNA (Coralville, USA): gapdh (Mm.PT.39a.1), β2m (Mm00437762_m1) and cd8b1 (Mm.PT49a.10182911). For this analysis, presymptomatic tissue was collected at 90 days of age and symptomatic at 120 days of age. The scientist performing the qPCR was blinded to the genotypes of the samples.
Nissl Staining
To visualize neurons, Nissl staining was performed on 4% formaldehyde fixed spinal cords sections. Sections were briefly immersed in a cresyl violet solution and subsequently in a 70% ethanol with 10% acetic acid. Slides were dehydrated by an increased ethanol concentration series and mounted with PerTex® (Histolab AB, Goteborg, Sweden). Images were collected by Zeiss Axio Imager M1 microscope (Carl Zeiss AG) with AxioCam Mrc5 camera (Carl Zeiss AG). The number of (motor) neurons was quantified by measurement of the soma area as visualized by cresyl violet staining in ImageJ (National Institute of Health) on multiple 40 μm thick sections in the ventral horn of the lumbar spinal cord. Characterisation of motor neurons occurred as previously (Fischer et al., 2004) of at least 5–10 ventral horns of the lumbar spinal cord of 2–4 mice per group. The scientist performing the Nissl staining and neuron quantification was blinded to the genotypes of the samples.
Immunohistochemistry
Mice were transcardially perfused with phosphate buffered saline (PBS) and subsequently with 4% formaldehyde. Spinal cords were post-fixed with 4% formaldehyde overnight at 4°C and transferred to 30% sucrose for an additional night. After snap freezing, tissue was sectioned by cryostat at 40 μm thickness and stained with a polyclonal antibody directed against ubiquitin (Dako, Glostrup, Denmark). Images were collected by Zeiss Axio Imager M1 microscope (Carl Zeiss AG) with AxioCam Mrc5 camera (Carl Zeiss AG). Ubiquitin immunopositive aggregates were counted per ventral horn using ImageJ of 2–6 ventral horns of the lumbar spinal cord of 2–4 mice per group and presented as the average of the number of aggregates per ventral horn. The scientist performing the immunohistochemistry and aggregate quantification was blinded to the genotypes of the samples.
Statistical Analysis
Analysis was performed with the statistical software package Prism Origin (GraphPad Software, La Jolla, USA). Survival was analyzed by Log-Rank testing. Differences between two groups were analyzed using a Student’s t-test. Differences between more than two groups were analyzed by ANOVA with Bonferroni correction for multiple testing. Significance was assumed at p < 0.05. Error bars represent the standard deviation.
Results
To assess the potential for β2m to have a functional role in ALS pathogenesis, we assessed gene expression in the spinal cords of non-transgenic, SOD1WT and SOD1G93A mice. We observed a strong increase in β2m gene expression during disease progression in SOD1G93A mice (Figure 1A). This increase is at least partly due to the increased neuron-specific gene expression of β2m, as a greater level of upregulation (10-fold) was identified by qPCR on neurons from SOD1G93A mice compared to neurons from SOD1WT mice isolated by laser dissection microscopy (Figure 1B). As we do not observe an increase of CD8+ T cells in the spinal cord of end stage SOD1G93A mice, as assessed by the gene expression analysis of CD8b1 (Figure 1C), these data indicate potential for a neuronal role for β2m in ALS.
Figure 1. Increased β2m gene expression in ALS mice. (A) Relative β2m gene expression in spinal cord of non-transgenic (ntg, n = 6) and SOD1WT controls (n = 6) compared to presymtomatic (presympt, n = 6), symptomatic (sympt, n = 6) and end stage (n = 6) SOD1G93A mice (ANOVA, Bonferroni post hoc). (B) Relative β2m gene expression in neurons isolated by laser dissection microscopy from the spinal cord of SOD1WT controls at 60 days (n = 2) and 130 days of age (n = 3) compared to neurons from SOD1G93A mice at 60 days (n = 3) and 130 days of age (n = 3; Student’s t-test). (C) Relative CD8b1 gene expression in the spinal cord of 150 day old non-transgenic mice (ntg, n = 5) and end stage (n = 5) SOD1G93A mice. *p < 0.05, **p < 0.01, ****p < 0.0001.
To determine whether β2m has an effect in ALS, we interbred β2m−/– mice with SOD1G93A mice and assessed disease progression in β2m−/– SOD1G93A, β2m+/– SOD1G93A and β2m+/+ SOD1G93A mice. The survival of β2m+/– SOD1G93A mice did not differ from β2m+/+ SOD1G93A littermates (data not shown). The complete genetic ablation of β2m did not affect onset of disease (data not shown), but significantly decreased average survival of SOD1G93A mice by 8.9 days (Figure 2A) and reduced disease duration by approximately 50% (Figure 2B). The decrease of survival in β2m−/– SOD1G93A mice demonstrated a protective role for β2m in ALS mice.
Figure 2. Decreased survival in β2m knockout ALS mice. (A) Survival analysis of β2m+/– SOD1G93A (n = 13, 154.9 ± 7.7 days) and β2m−/– SOD1G93A mice (n = 11, 146.0 ± 8.8 days; Log-Rank p = 0.009). (B) Disease duration of β2m+/– SOD1G93A (n = 9) and β2m−/– SOD1G93A mice (n = 8). *p < 0.05.
To assess whether genetic ablation of β2m alters pathology of SOD1G93A mice, we analyzed pathology in the spinal cords of end stage mice. Decreased numbers of motor neurons were observed in the end stage spinal cord of SOD1G93A and β2m−/– SOD1G93A mice (Figures 3A–C, quantified in Figure 3D), as were increased ubiquitin-positive aggregates (Figures 3E–G, quantified in Figure 3H). No differences were observed between the end stage pathology of SOD1G93A and β2m−/– SOD1G93A mice for motor neurons (Figures 3B, C) or ubiquitin immunoreactivity (Figures 3F, G). This shows that end stage β2m−/– SOD1G93A mice show the same extent of motor neuron loss and aggregate formation as end stage SOD1G93A mice, although disease progression is faster.
Figure 3. Unaltered end stage pathology in β2m-deficient SOD1G93A mice. Ventral horns of spinal cord sections of non-transgenic (ntg, n = 4; A and E) and SOD1G93A (n = 4; B and F) and β2m−/– SOD1G93A (n = 2; C and G) SOD1G93A mice. Nissl staining was used to visualize the (motor) neurons (A–C). The number of > 250 μm2 neurons and > 400 μm2 motor neurons per ventral horn are quantified in (D). Ubiquitin immunoreactivity in spinal cord sections of non-transgenic, SOD1G93A and β2m−/– SOD1G93A mice are quantified in (H) Dashed lines delineate the ventral horn. Scale bar = 100 µm. *p < 0.05, **p < 0.01, ***p < 0.001.
Discussion
Here we show that β2m is important in ALS mouse survival and that it is upregulated during disease in the spinal cord and by motor neurons. Upregulation of β2m in neuronal tissues has been reported previously when comparing spinal cord (Edstrom et al., 2004) and brain (VanGuilder Starkey et al., 2012) expression of aged rats to adult controls and in the spinal cord of axotomised rats (Maehlen et al., 1988; Olsson et al., 1989; Linda et al., 1998), which may suggest that stressed neurons increase β2m gene expression to increase plasticity. This concept fits well with reports of the role of β2m in neurons during development and plasticity (Huh et al., 2000; Bilousova et al., 2012), of the hippocampus and visual system (Huh et al., 2000) but not of the cerebellum (Letellier et al., 2008), and the delayed or impaired recovery of β2m knockout mice post axotomy (Linda et al., 1998; Oliveira et al., 2004) and sciatic nerve crush (Oliveira et al., 2004).
Impaired (peripheral) plasticity by β2m knockout may explain the decrease in survival detected in ALS mice in this study, as increased plasticity is protective in ALS mice and rats (Van Hoecke et al., 2012). A number of plasticity-promoting genetic or pharmacological strategies have proven successful in the past in ALS models, such as EphA4 knockdown and inhibition (Van Hoecke et al., 2012), and vascular endothelial growth factor (VEGF) administration in ALS rodents (Storkebaum et al., 2005).
With the use of a ubiquitous β2m knockout mouse we cannot exclude that the decrease of survival of ALS mice lacking β2m may be due to the effect of removing β2m in the immune system. β2m is necessary for the differentiation of CD8+ T cells and natural killer T (NKT) cells (Koller et al., 1990). The role of these cell types is not yet fully understood in ALS, as varying results are obtained for ALS mouse survival when mature lymphocytes are not present (Beers et al., 2008; Tada et al., 2011). Additionally, NKT cells may be associated to ALS disease pathology as impairments in NKT cells are reported in ALS mice (Finkelstein et al., 2011). That being said, qPCR analysis of CD8+ T cells does not suggest a role for these cells as CD8b1 gene expression is not increased in ALS spinal cords. Additionally, a role for CD8+ T cells may be predicted to be detrimental in contrast to our data demonstrating a detrimental role for β2m upon removal in ALS mice. Interestingly, β2m has been assessed previously as a biomarker in cerebrospinal fluid or venous blood samples from ALS patients, but with variable results (Brettschneider et al., 2008; Mitchell et al., 2009; Baciu et al., 2012).
The mechanism to which β2m contributes to neuronal plasticity is not fully understood, though it is proposed that it may be through paired-immunoglobulin like receptor-B (PirB) (VanGuilder Starkey et al., 2012). This receptor is located on axons, dendrites and neuronal somata (VanGuilder Starkey et al., 2012) and could thus easily facilitate plasticity. Additionally, β2m is localized at synapses and in synaptosomes (Shatz, 2009). Alternatively, β2m and PirB are associated with decreased plasticity and recovery in other neurodegenerative conditions such as stroke (Adelson et al., 2012), experimental autoimmune encephalomyelitis (EAE; Denic et al., 2012) and ischemia (Wang et al., 2012). These paradigms are largely affected by the immune system and the beneficial effect of β2m or PirB in these models may be due to the role of the immune system. This notion is supported by work by Linker et al. that show that reconstitution of CD8+ cells in β2m knockout mice delays the effect of EAE compared to β2m knockout littermates (Linker et al., 2005).
In conclusion, this work shows the detrimental effect of β2m knockout in ALS and identifies β2m signaling as a potential new direction for the development of therapeutic strategies counteracting ALS.
Author Contributions
Kim A. Staats and Susann Schönefeldt performed the murine behavioral analyses. Kim A. Staats and Marike Van Rillaer conducted the staining experiments. Kim A. Staats and Annelies Van Hoecke analyzed gene expression of motor neurons excised by laser dissection microscopy. Philip Van Damme, Wim Robberecht, Adrian Liston and Ludo Van Den Bosch supervised and designed the experiments. Kim A. Staats, Adrian Liston and Ludo Van Den Bosch wrote the manuscript. All authors approved the final version of the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported by grants from the “Fund for Scientific Research Flanders” (FWO-Vlaanderen), the University of Leuven (KU Leuven), the Belgian Government Interuniversity Attraction Poles, programme P7/16 of the Belgian Federal Science Policy Office) and the European Community’s Health Seventh Framework Programme (FP7/2007-2013 under grant agreement 259867). Philip Van Damme holds a clinical investigatorship of the FWO-Vlaanderen. Wim Robberecht is supported through the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders.
References
Adelson, J. D., Barreto, G. E., Xu, L., Kim, T., Brott, B. K., Ouyang, Y. B., et al. (2012). Neuroprotection from stroke in the absence of MHCI or PirB. Neuron 73, 1100–1107. doi: 10.1016/j.neuron.2012.01.020
Baciu, C., Thompson, K. J., Mougeot, J. L., Brooks, B. R., and Weller, J. W. (2012). The LO-BaFL method and ALS microarray expression analysis. BMC Bioinformatics 13:244. doi: 10.1186/1471-2105-13-244
Beers, D. R., Henkel, J. S., Zhao, W., Wang, J., and Appel, S. H. (2008). CD4+ T cells support glial neuroprotection, slow disease progression and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U S A 105, 15558–15563. doi: 10.1073/pnas.0807419105
Bilousova, T., Dang, H., Xu, W., Gustafson, S., Jin, Y., Wickramasinghe, L., et al. (2012). Major histocompatibility complex class I molecules modulate embryonic neuritogenesis and neuronal polarization. J. Neuroimmunol. 247, 1–8. doi: 10.1016/j.jneuroim.2012.03.008
Brettschneider, J., Mogel, H., Lehmensiek, V., Ahlert, T., Sussmuth, S., Ludolph, A. C., et al. (2008). Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem. Res. 33, 2358–2363. doi: 10.1007/s11064-008-9742-5
Denic, A., Pirko, I., Wootla, B., Bieber, A., Macura, S., and Rodriguez, M. (2012). Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis. Brain Pathol. 22, 698–708. doi: 10.1111/j.1750-3639.2012.00576.x
Edstrom, E., Kullberg, S., Ming, Y., Zheng, H., and Ulfhake, B. (2004). MHC class I, beta2 microglobulin and the INF-gamma receptor are upregulated in aged motoneurons. J. Neurosci. Res. 78, 892–900. doi: 10.1002/jnr.20341
Elmer, B. M., and Mcallister, A. K. (2012). Major histocompatibility complex class I proteins in brain development and plasticity. Trends Neurosci. 35, 660–670. doi: 10.1016/j.tins.2012.08.001
Finkelstein, A., Kunis, G., Seksenyan, A., Ronen, A., Berkutzki, T., Azoulay, D., et al. (2011). Abnormal changes in NKT cells, the IGF-1 axis and liver pathology in an animal model of ALS. PLoS One 6:e22374. doi: 10.1371/journal.pone.0022374
Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A., Wang, M., Castellano-Sanchez, A., et al. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232–240. doi: 10.1016/j.expneurol.2003.10.004
Huh, G. S., Boulanger, L. M., Du, H., Riquelme, P. A., Brotz, T. M., and Shatz, C. J. (2000). Functional requirement for class I MHC in CNS development and plasticity. Science 290, 2155–2159. doi: 10.1126/science.290.5499.2155
Julien, J. P., and Kriz, J. (2006). Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1013–1024. doi: 10.1016/j.bbadis.2006.03.006
Koller, B. H., Marrack, P., Kappler, J. W., and Smithies, O. (1990). Normal development of mice deficient in beta 2M, MHC class I proteins and CD8+ T cells. Science 248, 1227–1230. doi: 10.1126/science.2112266
Letellier, M., Willson, M. L., Gautheron, V., Mariani, J., and Lohof, A. M. (2008). Normal adult climbing fiber monoinnervation of cerebellar Purkinje cells in mice lacking MHC class I molecules. Dev. Neurobiol. 68, 997–1006. doi: 10.1002/dneu.20639
Linda, H., Hammarberg, H., Cullheim, S., Levinovitz, A., Khademi, M., and Olsson, T. (1998). Expression of MHC class I and beta2-microglobulin in rat spinal motoneurons: regulatory influences by IFN-gamma and axotomy. Exp. Neurol. 150, 282–295. doi: 10.1006/exnr.1997.6768
Linda, H., Hammarberg, H., Piehl, F., Khademi, M., and Olsson, T. (1999). Expression of MHC class I heavy chain and beta2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons. J. Neuroimmunol. 101, 76–86. doi: 10.1016/s0165-5728(99)00135-6
Linker, R. A., Rott, E., Hofstetter, H. H., Hanke, T., Toyka, K. V., and Gold, R. (2005). EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. Neurobiol. Dis. 19, 218–228. doi: 10.1016/j.nbd.2004.12.017
Logroscino, G., Traynor, B. J., Hardiman, O., Chio, A., Mitchell, D., Swingler, R. J., et al. (2010). Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 81, 385–390. doi: 10.1136/jnnp.2009.183525
Maehlen, J., Schroder, H. D., Klareskog, L., Olsson, T., and Kristensson, K. (1988). Axotomy induces MHC class I antigen expression on rat nerve cells. Neurosci. Lett. 92, 8–13. doi: 10.1016/0304-3940(88)90733-1
Mitchell, R. M., Freeman, W. M., Randazzo, W. T., Stephens, H. E., Beard, J. L., Simmons, Z., et al. (2009). A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 72, 14–19. doi: 10.1212/01.wnl.0000333251.36681.a5
Oliveira, A. L., Thams, S., Lidman, O., Piehl, F., Hokfelt, T., Karre, K., et al. (2004). A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc. Natl. Acad. Sci. U S A 101, 17843–17848. doi: 10.1073/pnas.0408154101
Olsson, T., Kristensson, K., Ljungdahl, A., Maehlen, J., Holmdahl, R., and Klareskog, L. (1989). Gamma-interferon-like immunoreactivity in axotomized rat motor neurons. J. Neurosci. 9, 3870–3875.
Shatz, C. J. (2009). MHC class I: an unexpected role in neuronal plasticity. Neuron 64, 40–45. doi: 10.1016/j.neuron.2009.09.044
Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M. P., Appelmans, S., Oh, H., et al. (2005). Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8, 85–92. doi: 10.1038/nn1360
Tada, S., Okuno, T., Yasui, T., Nakatsuji, Y., Sugimoto, T., Kikutani, H., et al. (2011). Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J. Neuroinflammation 8:19. doi: 10.1186/1742-2094-8-19
Thams, S., Brodin, P., Plantman, S., Saxelin, R., Karre, K., and Cullheim, S. (2009). Classical major histocompatibility complex class I molecules in motoneurons: new actors at the neuromuscular junction. J. Neurosci. 29, 13503–13515. doi: 10.1523/jneurosci.0981-09.2009
VanGuilder Starkey, H. D., Van Kirk, C. A., Bixler, G. V., Imperio, C. G., Kale, V. P., Serfass, J. M., et al. (2012). Neuroglial expression of the MHCI pathway and PirB receptor is upregulated in the hippocampus with advanced aging. J. Mol. Neurosci. 48, 111–126. doi: 10.1007/s12031-012-9783-8
Van Hoecke, A., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K. A., Laird, A. S., et al. (2012). EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 18, 1418–1422. doi: 10.1038/nm.2901
Keywords: beta-2 microglobulin, amyotrophic lateral sclerosis, motor neuron, neurodegeneration, motor neuron disease
Citation: Staats KA, Schönefeldt S, Van Rillaer M, Van Hoecke A, Van Damme P, Robberecht W, Liston A and Van Den Bosch L (2013) Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis. Front. Cell. Neurosci. 7:249. doi: 10.3389/fncel.2013.00249
Received: 31 August 2013; Accepted: 20 November 2013;
Published online: 10 December 2013.
Edited by:
Ricardo Tapia, Universidad Nacional Autónoma de México, MexicoReviewed by:
Luis H. Barbeito, Institut Pasteur de Montevideo, UruguayMoses Rodriguez, Mayo Clinic, USA
Copyright © 2013 Staats, Schönefeldt, Van Rillaer, Van Hoecke, Van Damme, Robberecht, Liston and Van Den Bosch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adrian Liston, VIB Autoimmune Genetics Laboratory, KU Leuven, Campus Gasthuisberg O&N2, Herestraat 49 - PB 1026, B-3000 Leuven, Belgium e-mail: adrian.liston@vib-kuleuven.be
Ludo Van Den Bosch, Laboratory of Neurobiology, Campus Gasthuisberg O&N4, Herestraat 49 - PB 1026, B-3000 Leuven, Belgium e-mail: ludo.vandenbosch@vibkuleuven.be
†These authors have contributed equally to the work.